Revolutionary combination drug increases survival rate for advanced lung cancer patients with EGFR mutation

Amivantamab-Lazertinib Leads to Improved Progression-Free Survival in EGFR-Mutated Advanced NSCLC

Non-small cell lung cancer (NSCLC) is a type of cancer that affects the lungs and is responsible for most lung cancer cases. EGFR-mutated advanced NSCLC is a subtype of NSCLC that can be challenging to treat. However, a recent phase 3 trial has shown that amivantamab-lazertinib can lead to improved progression-free survival compared to osimertinib as a first-line treatment for EGFR-mutated advanced NSCLC.

Study Details

The study was conducted by medical professionals from the Yonsei Cancer Center in Seoul, South Korea, and involved 1074 patients with previously untreated EGFR-mutated, locally advanced, or metastatic NSCLC. Patients were randomly allocated to receive one of three treatments: amivantamab-lazertinib (open-label), osimertinib (blinded), or lazertinib (blinded) in a 2:2:1 ratio (429, 429, and 216 patients, respectively).

Results

The study found that patients who received amivantamab-lazertinib had a significantly longer median progression-free survival than those who received osimertinib (23.7 versus 16.6 months) with a hazard ratio for disease progression or death of 0.70. Additionally, the amivantamab-lazertinib group had an objective response rate of 86%, compared to 85% in the osimertinib group. The median duration of response in the amivantamab-lazertinib group was 25.8 months, compared to 16.8 months in the osimertinib group.

Adverse Events

EGFR-related toxic effects were the predominant adverse events. The incidence of discontinuation of all agents due to treatment-related adverse events was 10% and 3% with amivantamab-lazertinib and osimertinib, respectively.

Overall Survival

While the study did not find a significant difference in overall survival between the amivantamab-lazertinib and osimertinib groups in a planned interim analysis, the study is ongoing, and more data is expected in the future.

Conclusion

The study demonstrates that amivantamab-lazertinib is a promising first-line treatment for patients with EGFR-mutated advanced NSCLC and can improve progression-free survival compared to osimertinib. However, as with any medical treatment, it is essential to weigh the potential benefits against the risks of adverse events and consult with a healthcare professional to determine the best course of treatment for each individual patient.

Long-Tail Keywords

EGFR-mutated advanced non-small cell lung cancer
Amivantamab-lazertinib
Osimertinib
Progression-free survival
Mutated lung cancer
Objective response rate
Overall survival
Adverse events
First-line treatment
Lung cancer patients
Healthcare treatments
Medical professionals

Originally Post From https://www.pulmonologyadvisor.com/news/amivantamab-lazertinib-ups-survival-in-egfr-mutated-advanced-lung-cancer/